Chronic Kidney Disease Drug Developers Jockey For Position In Era Of Change

Upheaval in the chronic kidney disease market ranging from FDA’s ongoing re-evaluation of the safety of erythropoietin stimulating agents to impending major changes in Medicare reimbursement for dialysis patients is resulting in a chain reaction of adjustments in drug development strategies.